Moleculin Biotech vs Pyxis Oncology
MBRX and PYXS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MBRX and PYXS compare
Moleculin Biotech and Pyxis Oncology are about the same size, with market caps of $133M and $120M.
Pyxis Oncology scores higher on the StockData Score (5 against 4 for Moleculin Biotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MBRX | PYXS |
|---|---|---|
| Size and price | ||
| Market cap | $133M | $120M |
| Share price | $6.83 | $1.44 |
| Change, 1 year | −96.9% | −67.0% |
| Change, 5 years | −100.0% | −88.8% |
| Beta (5Y) | −1.10 | 3.15 |
| Employees | 150K | 56 |
| StockData Score | ||
| Total score | 4 | 5 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 4 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 11.5× | 10.5× (better) |
| Profitability | ||
| Return on equity | −524% | −179% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 0.94 | 1.34 (better) |
| Altman Z-score | −11.19 (better) | −16.21 |
| Piotroski F-score | 3 (better) | 1 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 0.05% | 40.9% |
| Held by insiders | 20.2% | 20.4% |
| Insider net buying, 12 months | – | −$107K |
| Short interest, % of float | 0.35% | 6.8% |
Go deeper
- MBRX stock overview
- MBRX income statement
- MBRX valuation and score
- PYXS stock overview
- PYXS income statement
- PYXS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.